← All Jobs
Posted Apr 1, 2026

Head of In Silico Drug Toxicity/VP of Toxicology

Apply Now ✨

About the Company

Deep Origin is building an operating system for science that transforms how life science research is conducted. Led by Michael Antonov, co-founder of Oculus, and backed by Formic Ventures, we are redefining the infrastructure behind modern drug discovery.

We are now building the next-generation platform for predicting drug toxicity in silico,  transforming how pharmaceutical companies evaluate safety before clinical trials. Our mission is to reduce failure rates, accelerate drug development, and eliminate unnecessary animal testing through high-fidelity computational models of human biology.

We are not building incremental QSAR tools. We are building foundational infrastructure for predictive toxicology in the age of AI, systems biology, and large-scale computation. 


About the Role

We are seeking a Head of In Silico Drug Toxicity to own, define, and scale our computational toxicology platform end-to-end.

This role operates as the general manager of the platform — effectively a CEO of the product — with full ownership across scientific vision, technical architecture, product strategy, and execution.

You will work cross-functionally with ML/AI teams, computational biologists, toxicologists, engineers, and commercial teams to build a category-defining platform for predictive toxicology.

This role requires both deep technical leadership and executive-level strategic thinking, with the ability to translate cutting-edge science into scalable, enterprise-ready systems.

Requirements

Technical Depth in Computational Toxicology 

Deep expertise in one or more of:

Domain & Industry Knowledge.

Executive Leadership

Builder & Entrepreneurial Mindset

Key Responsibilities

Scientific & Technical Vision

Platform & Product Leadership

Innovation & Data Strategy

Customer & External Leadership

Team & Cross-Functional Leadership

Values & Working Style

Why This Role Matters Now

Deep Origin is entering a phase where scientific innovation, platform infrastructure, and commercial partnerships must scale simultaneously.

This role will define the foundation of our computational toxicology platform, shaping not only our product but how the industry approaches drug safety.

Benefits